Article Details
Retrieved on: 2021-04-10 11:15:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The proceeds of the transaction will be utilized to advance ImmuneOncia's Phase I and II clinical studies of IMC-001, a PD-L1 monoclonal antibody, ...
Article found on: fintechzoom.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here